SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk

Neveen A. Said, Ida Najwer, Matthew J. Socha, David J Fulton, Samuel C. Mok, Kouros Motamed

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The interplay between peritoneal mesothelial cells and ovarian cancer cells is critical for the initiation and peritoneal dissemination of, and ascites formation in, ovarian cancer. The production of lysophosphatidic acid (LPA) by both peritoneal mesothelial cells and ovarian cancer cells has been shown to promote metastatic phenotype in ovarian cancer. Herein, we report that exogenous addition or ectopic overexpression of the matricellular protein SPARC (secreted protein acidic and rich in cysteine) significantly attenuated LPA-induced proliferation, chemotaxis, and invasion in both highly metastatic SKOV3 and less metastatic OVCAR3 ovarian cancer cell lines. SPARC appears to modulate these functions, at least in part, through the regulation of LPA receptor levels and the attenuation of extracellular signal-regulated kinase (ERK) 1/2 and protein kinase B/AKT signaling. Moreover, our results show that SPARC not only significantly inhibited both basal and LPA-induced interleukin (IL) 6 production in both cell lines but also attenuated IL-6-induced mitogenic, chemotactic, and proinvasive effects, in part, through significant suppression of ERK1/2 and, to a lesser extent, of signal transducers and activators of transcription 3 signaling pathways. Our results strongly suggest that SPARC exerts a dual inhibitory effect on LPA-induced mesothelial-ovarian cancer cell crosstalk through the regulation of both LPA-induced IL-6 production and function. Taken together, our findings underscore the use of SPARC as a potential therapeutic candidate in peritoneal ovarian carcinomatosis.

Original languageEnglish (US)
Pages (from-to)23-35
Number of pages13
JournalNeoplasia
Volume9
Issue number1
DOIs
StatePublished - Jan 1 2007

Fingerprint

Ovarian Neoplasms
Cysteine
Interleukin-6
Proteins
Lysophosphatidic Acid Receptors
Cell Line
STAT3 Transcription Factor
Proto-Oncogene Proteins c-akt
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1
Chemotaxis
Ascites
lysophosphatidic acid
Carcinoma
Phenotype

Keywords

  • IL-6
  • LPA
  • Mesothelial cells
  • Ovarian cancer
  • SPARC

ASJC Scopus subject areas

  • Cancer Research

Cite this

Said, N. A., Najwer, I., Socha, M. J., Fulton, D. J., Mok, S. C., & Motamed, K. (2007). SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. Neoplasia, 9(1), 23-35. https://doi.org/10.1593/neo.06658

SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. / Said, Neveen A.; Najwer, Ida; Socha, Matthew J.; Fulton, David J; Mok, Samuel C.; Motamed, Kouros.

In: Neoplasia, Vol. 9, No. 1, 01.01.2007, p. 23-35.

Research output: Contribution to journalArticle

Said, NA, Najwer, I, Socha, MJ, Fulton, DJ, Mok, SC & Motamed, K 2007, 'SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk', Neoplasia, vol. 9, no. 1, pp. 23-35. https://doi.org/10.1593/neo.06658
Said, Neveen A. ; Najwer, Ida ; Socha, Matthew J. ; Fulton, David J ; Mok, Samuel C. ; Motamed, Kouros. / SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. In: Neoplasia. 2007 ; Vol. 9, No. 1. pp. 23-35.
@article{4b175c42d10842d09b5200c8a01dbc0b,
title = "SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk",
abstract = "The interplay between peritoneal mesothelial cells and ovarian cancer cells is critical for the initiation and peritoneal dissemination of, and ascites formation in, ovarian cancer. The production of lysophosphatidic acid (LPA) by both peritoneal mesothelial cells and ovarian cancer cells has been shown to promote metastatic phenotype in ovarian cancer. Herein, we report that exogenous addition or ectopic overexpression of the matricellular protein SPARC (secreted protein acidic and rich in cysteine) significantly attenuated LPA-induced proliferation, chemotaxis, and invasion in both highly metastatic SKOV3 and less metastatic OVCAR3 ovarian cancer cell lines. SPARC appears to modulate these functions, at least in part, through the regulation of LPA receptor levels and the attenuation of extracellular signal-regulated kinase (ERK) 1/2 and protein kinase B/AKT signaling. Moreover, our results show that SPARC not only significantly inhibited both basal and LPA-induced interleukin (IL) 6 production in both cell lines but also attenuated IL-6-induced mitogenic, chemotactic, and proinvasive effects, in part, through significant suppression of ERK1/2 and, to a lesser extent, of signal transducers and activators of transcription 3 signaling pathways. Our results strongly suggest that SPARC exerts a dual inhibitory effect on LPA-induced mesothelial-ovarian cancer cell crosstalk through the regulation of both LPA-induced IL-6 production and function. Taken together, our findings underscore the use of SPARC as a potential therapeutic candidate in peritoneal ovarian carcinomatosis.",
keywords = "IL-6, LPA, Mesothelial cells, Ovarian cancer, SPARC",
author = "Said, {Neveen A.} and Ida Najwer and Socha, {Matthew J.} and Fulton, {David J} and Mok, {Samuel C.} and Kouros Motamed",
year = "2007",
month = "1",
day = "1",
doi = "10.1593/neo.06658",
language = "English (US)",
volume = "9",
pages = "23--35",
journal = "Neoplasia (United States)",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk

AU - Said, Neveen A.

AU - Najwer, Ida

AU - Socha, Matthew J.

AU - Fulton, David J

AU - Mok, Samuel C.

AU - Motamed, Kouros

PY - 2007/1/1

Y1 - 2007/1/1

N2 - The interplay between peritoneal mesothelial cells and ovarian cancer cells is critical for the initiation and peritoneal dissemination of, and ascites formation in, ovarian cancer. The production of lysophosphatidic acid (LPA) by both peritoneal mesothelial cells and ovarian cancer cells has been shown to promote metastatic phenotype in ovarian cancer. Herein, we report that exogenous addition or ectopic overexpression of the matricellular protein SPARC (secreted protein acidic and rich in cysteine) significantly attenuated LPA-induced proliferation, chemotaxis, and invasion in both highly metastatic SKOV3 and less metastatic OVCAR3 ovarian cancer cell lines. SPARC appears to modulate these functions, at least in part, through the regulation of LPA receptor levels and the attenuation of extracellular signal-regulated kinase (ERK) 1/2 and protein kinase B/AKT signaling. Moreover, our results show that SPARC not only significantly inhibited both basal and LPA-induced interleukin (IL) 6 production in both cell lines but also attenuated IL-6-induced mitogenic, chemotactic, and proinvasive effects, in part, through significant suppression of ERK1/2 and, to a lesser extent, of signal transducers and activators of transcription 3 signaling pathways. Our results strongly suggest that SPARC exerts a dual inhibitory effect on LPA-induced mesothelial-ovarian cancer cell crosstalk through the regulation of both LPA-induced IL-6 production and function. Taken together, our findings underscore the use of SPARC as a potential therapeutic candidate in peritoneal ovarian carcinomatosis.

AB - The interplay between peritoneal mesothelial cells and ovarian cancer cells is critical for the initiation and peritoneal dissemination of, and ascites formation in, ovarian cancer. The production of lysophosphatidic acid (LPA) by both peritoneal mesothelial cells and ovarian cancer cells has been shown to promote metastatic phenotype in ovarian cancer. Herein, we report that exogenous addition or ectopic overexpression of the matricellular protein SPARC (secreted protein acidic and rich in cysteine) significantly attenuated LPA-induced proliferation, chemotaxis, and invasion in both highly metastatic SKOV3 and less metastatic OVCAR3 ovarian cancer cell lines. SPARC appears to modulate these functions, at least in part, through the regulation of LPA receptor levels and the attenuation of extracellular signal-regulated kinase (ERK) 1/2 and protein kinase B/AKT signaling. Moreover, our results show that SPARC not only significantly inhibited both basal and LPA-induced interleukin (IL) 6 production in both cell lines but also attenuated IL-6-induced mitogenic, chemotactic, and proinvasive effects, in part, through significant suppression of ERK1/2 and, to a lesser extent, of signal transducers and activators of transcription 3 signaling pathways. Our results strongly suggest that SPARC exerts a dual inhibitory effect on LPA-induced mesothelial-ovarian cancer cell crosstalk through the regulation of both LPA-induced IL-6 production and function. Taken together, our findings underscore the use of SPARC as a potential therapeutic candidate in peritoneal ovarian carcinomatosis.

KW - IL-6

KW - LPA

KW - Mesothelial cells

KW - Ovarian cancer

KW - SPARC

UR - http://www.scopus.com/inward/record.url?scp=33846840798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846840798&partnerID=8YFLogxK

U2 - 10.1593/neo.06658

DO - 10.1593/neo.06658

M3 - Article

C2 - 17325741

AN - SCOPUS:33846840798

VL - 9

SP - 23

EP - 35

JO - Neoplasia (United States)

JF - Neoplasia (United States)

SN - 1522-8002

IS - 1

ER -